Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Outperformance, Underperformance and Volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Seattle Genetics and Takeda Pharmaceutical Limited announced a successful trial on mature T-Cell lymphoma

October 1, 2018 0

Seattle Genetics (SGEN) and Takeda Pharmaceutical Limited (TKPYY) announced results from Phase 3 ECHELON-2 clinical trial evaluating Adcetris …

Antisense investigational product demonstrates successful results treating a life-threatening disease with no current treatment

September 27, 2018 0

The high risk of premature death from cardiovascular disease is believed to be caused by an …

AstraZeneca: Advancing and improving Stage III lung cancer treatments

September 26, 2018 0

Stage III (locally-advanced) NSCLC is commonly divided into three sub-categories: IIIA, IIIB and IIIC, defined by …

Three important news

September 25, 2018 0

The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across …

The medical news of the year comes at the hands of Abott

September 24, 2018 0

While preparing The Week in Review issue from Prohost, our attention shifted towards historical news about …

A Bayer testing of Compugen’s checkpoint protein in human trial boosted our expectations for Compugen’s resurrection

September 21, 2018 0

Compugen Again On Sept 10, 2018, we posted in The Week in Review #28 news we found …

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

September 20, 2018 0

Portola Pharmaceuticals Appoints Scott Garland as President and Chief Executive Officer, Effective October 8, 2018. Portola (PTLA) appointed …

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

September 20, 2018 0

Exelixis’ (EXEL) partner Ipsen Biopharmaceuticals Canada Inc. received approval of Cabometyx®(cabozantinib) tablets from Health Canada for adults with …

CRISPR Therapeutics’ new collaboration targeting Diabetes

September 19, 2018 0

CRISPR Gene Editing Beyond Bringing Cures to disease-causing genes, CRISPR gene editing technology can change the way diseases …

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver disease

September 18, 2018 2

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic …

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

September 17, 2018 0

Phase 2 clinical trial data of argenx’s (ARGX) product Efgartigimod (ARGX-113) in adult patients with primary immune …

AcelRx Pharmaceuticals: A small currently highlighted firm

September 14, 2018 0

Today, we see are observing an increased interest in AcelRx Pharmaceuticals (ACRX). The increased investors’ activity …

Gilead Sciences: In pursuit of cures for intractable diseases

September 13, 2018 0

Gilead Sciences (GILD) has news that we felt good about it for a company that saved …

CRISPR gene editing firms clear investors’ confusion

September 12, 2018 0

Playing buy and sell games with the CRISPR gene editing stocks is sometimes based on scientific …

Amgen and AstraZeneca have in hand a very much needed Asthma drug

September 11, 2018 0

In the Week in Review posted yesterday on our website that is experiencing several attempts on …

What is looking good in the aggressive portfolio

September 10, 2018 0

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with …

Gilead and Galapagos have good news for patients with severely active Ankylosing Spondylitis

September 7, 2018 0

Gilead Sciences’ (GILD) and Galapagos’ (GLPG) product filgotinib – a highly selective JAK1 inhibitor has met …

What happened to Sangamo yesterday?

September 6, 2018 0

The disease, mucopolysaccharidosis (MPS) type II, also known as the horrible Hunter syndrome is a killer …

Outperforming, favorite, and undervalued biotech firms

September 3, 2018 0

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Outperformance, Underperformance and Volatility

Seattle Genetics and Takeda Pharmaceutical Limited announced a successful trial on mature T-Cell lymphoma

Antisense investigational product demonstrates successful results treating a life-threatening disease with no current treatment

AstraZeneca: Advancing and improving Stage III lung cancer treatments

Three important news

The medical news of the year comes at the hands of Abott

A Bayer testing of Compugen’s checkpoint protein in human trial boosted our expectations for Compugen’s resurrection

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

CRISPR Therapeutics’ new collaboration targeting Diabetes

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver disease

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

AcelRx Pharmaceuticals: A small currently highlighted firm

Gilead Sciences: In pursuit of cures for intractable diseases

CRISPR gene editing firms clear investors’ confusion

Amgen and AstraZeneca have in hand a very much needed Asthma drug

What is looking good in the aggressive portfolio

Gilead and Galapagos have good news for patients with severely active Ankylosing Spondylitis

What happened to Sangamo yesterday?

Outperforming, favorite, and undervalued biotech firms